Fintel reports that on February 20, 2025, B. Riley Securities initiated coverage of Electromed (NYSEAM:ELMD) with a Buy ...

B. Riley analyst Kyle Bauser initiated coverage of Electromed (ELMD) with a Buy rating and $38 price target Electromed is a profitable, ...

B. Riley launched its coverage of Electromed (OTCQB:EMED) with a Buy recommendation and a $38 per share target, arguing that the company, being the final remaining pure-play stock in a market for a ...

StockNews.com lowered shares of Electromed (NYSE:ELMD – Free Report) from a strong-buy rating to a buy rating in a report issued on Wednesday morning. Electromed Stock Performance NYSE ELMD opened at ...

Facing a Shift in Market Trends?

NEW PRAGUE, Minn., February 11, 2025--Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial ...

Lake Street analyst Brooks O’Neil raised the firm’s price target on Electromed (ELMD) to $36 from $33 and keeps a Buy rating on the shares, ...

Electromed, Inc. (NYSEMKT:ELMD) engages in the manufacturing of airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care.

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will release its ...

Electromed continues to focus on its core Homecare segment, which achieved 15.2% year-over-year revenue growth to $14.6M. The average annualized revenue per direct sales representative stood at $ ...

Good afternoon, and welcome to the Electromed Second Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, this event is being ...

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and six months ...